{"id":"NCT00796614","sponsor":"Boehringer Ingelheim","briefTitle":"Study to Evaluate the Efficacy and Safety of Tamsulosin in Children With Neurogenic Bladder","officialTitle":"A Phase IIb/III, Multi-centre, Double-blind, Randomised, Placebo-controlled, Dose Ranging Study of Tamsulosin Hydrochloride (Low, Medium and High Dose) as Treatment in Children With Neuropathic Bladder for Three Months","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2008-01","primaryCompletion":"2009-02","completion":"2009-02","firstPosted":"2008-11-24","resultsPosted":"2012-09-12","lastUpdate":"2015-10-29"},"enrollment":231,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Bladder, Neurogenic"],"interventions":[{"type":"DRUG","name":"tamsulosin hydrochloride","otherNames":["Flomax","Omnic"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Low dose","type":"EXPERIMENTAL"},{"label":"Medium dose","type":"EXPERIMENTAL"},{"label":"High dose","type":"EXPERIMENTAL"}],"summary":"Aim of this study is to evaluate the efficacy and safety of a range of doses of tamsulosin hydrochloride as treatment in children with an elevated detrusor leak point pressure associated with a known neurological deficit","primaryOutcome":{"measure":"Response to Treatment Defined as Patients Who Decrease Their Detrusor Leak Point Pressure (LPP) to <40 cm H2O Based Upon Two Evaluations on the Same Day.","timeFrame":"Week 14","effectByArm":[{"arm":"Placebo","deltaMin":35.3,"sd":null},{"arm":"Tamsulosin - Low Dose Level","deltaMin":45.7,"sd":null},{"arm":"Tamsulosin - Medium Dose Level","deltaMin":27.3,"sd":null},{"arm":"Tamsulosin - High Dose Level","deltaMin":42.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.5388"},{"comp":"OG000 vs OG002","p":"0.3430"},{"comp":"OG000 vs OG003","p":"0.5209"},{"comp":"OG000 vs OG001 vs OG002 vs OG003","p":"0.9436"}]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":52,"countries":["United States","Belgium","Brazil","Germany","India","Italy","Mexico","Philippines","Russia","South Africa","South Korea","Spain","Ukraine"]},"refs":{"pmids":[],"seeAlso":["http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Flomax+Caps/Flomax.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":41},"commonTop":["Urinary tract infection","Vomiting","Nasopharyngitis","Headache","Influenza"]}}